NCT02434029View on ClinicalTrials.gov

Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis

PHASE3CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

November 11, 2015

Primary Completion Date

August 4, 2016

Study Completion Date

October 4, 2016

Conditions
Eosinophilic Esophagitis
Interventions
DRUG

Budesonide 1mg orodispersible tablet twice daily

DRUG

Placebo orodispersible tablet twice daily

Trial Locations (1)

20249

Center for Digestive Diseases Eppendorf, Hamburg

Sponsors
All Listed Sponsors
lead

Dr. Falk Pharma GmbH

INDUSTRY